Matthew
Golabek
Senior Investigative Analyst
Hetherington Group
Mr. Matthew Golabek specializes in online background investigations and risk assessments, cutting through volumes of online data to deliver what the client wants, when the client needs it. As a senior investigative analyst, Mr. Golabek has a keen eye for extracting content from social media accounts, tracking activities, and monitoring subjects for clients from a wide range of industries, including pharmaceutical, technological, retail, and entertainment.
Mr. Golabek is a contributor to Hg’s newsletter, Data2Know, and has years of experience in the design, development, and delivery of specialized training to various organizations such as the Department of Defense, the FBI, ATF, DEA, and other state, local, or federal law enforcement groups.
A key highlight of Mr. Golabek’s career was assisting in the world-class Operation Vax (OPVAX). OPVAX evolved into a collaboration of 75+ industry leaders and public agencies that collaborated at the height of the COVID-19 pandemic. Comprised of C-Suite healthcare, pharmaceutical, transportation, cybersecurity, and high-ranking Department of Defense personnel, they convened remotely over the course of 11 months, and their services led to the successful rollout of the vaccine home and abroad.
Mr. Golabek is a contributor to Hg’s newsletter, Data2Know, and has years of experience in the design, development, and delivery of specialized training to various organizations such as the Department of Defense, the FBI, ATF, DEA, and other state, local, or federal law enforcement groups.
A key highlight of Mr. Golabek’s career was assisting in the world-class Operation Vax (OPVAX). OPVAX evolved into a collaboration of 75+ industry leaders and public agencies that collaborated at the height of the COVID-19 pandemic. Comprised of C-Suite healthcare, pharmaceutical, transportation, cybersecurity, and high-ranking Department of Defense personnel, they convened remotely over the course of 11 months, and their services led to the successful rollout of the vaccine home and abroad.